Allogene Therapeutics Analyst Ratings
Allogene Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
07/12/2023 | 212.77% | Truist Securities | $20 → $18 | Maintains | Buy |
06/26/2023 | 386.53% | Oppenheimer | → $28 | Assumes | → Outperform |
06/20/2023 | 299.65% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
06/16/2023 | 508.17% | Canaccord Genuity | → $35 | Reiterates | Buy → Buy |
06/05/2023 | 160.64% | JMP Securities | → $15 | Reiterates | → Market Outperform |
06/05/2023 | 160.64% | EF Hutton | → $15 | Reiterates | Buy → Buy |
05/26/2023 | 160.64% | EF Hutton | → $15 | Reiterates | Buy → Buy |
05/05/2023 | 160.64% | JMP Securities | $19 → $15 | Maintains | Outperform |
05/05/2023 | 299.65% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
05/04/2023 | 30.32% | Stifel | $8 → $7.5 | Maintains | Hold |
05/04/2023 | 160.64% | RBC Capital | → $15 | Reiterates | → Outperform |
04/20/2023 | 299.65% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
04/18/2023 | 230.15% | JMP Securities | → $19 | Reiterates | → Market Outperform |
04/17/2023 | 160.64% | EF Hutton | → $15 | Maintains | Buy |
04/04/2023 | 299.65% | HC Wainwright & Co. | $29 → $23 | Maintains | Buy |
03/21/2023 | 4.26% | Bernstein | → $6 | Initiates Coverage On | → Market Perform |
03/02/2023 | 438.66% | Goldman Sachs | $35 → $31 | Maintains | Buy |
03/02/2023 | 230.15% | JMP Securities | $23 → $19 | Maintains | Market Perform |
03/01/2023 | 282.28% | RBC Capital | $32 → $22 | Maintains | Outperform |
03/01/2023 | 386.53% | Oppenheimer | $32 → $28 | Maintains | Outperform |
03/01/2023 | 438.66% | Goldman Sachs | $35 → $31 | Maintains | Buy |
03/01/2023 | 160.64% | EF Hutton | → $15 | Reiterates | → Buy |
01/24/2023 | 91.14% | JP Morgan | $20 → $11 | Upgrades | Neutral → Overweight |
01/06/2023 | 108.51% | Baird | → $12 | Upgrades | Neutral → Outperform |
01/05/2023 | 160.64% | EF Hutton | → $15 | Initiates Coverage On | → Buy |
12/12/2022 | 56.39% | B of A Securities | → $9 | Downgrades | Buy → Underperform |
11/21/2022 | 403.91% | HC Wainwright & Co. | $43 → $29 | Maintains | Buy |
09/22/2022 | 212.77% | B. Riley Securities | $21 → $18 | Maintains | Buy |
08/10/2022 | 508.17% | Oppenheimer | $40 → $35 | Maintains | Outperform |
08/10/2022 | 456.04% | RBC Capital | $35 → $32 | Maintains | Outperform |
08/10/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
07/15/2022 | 456.04% | Goldman Sachs | $9 → $32 | Upgrades | Neutral → Buy |
06/03/2022 | 91.14% | Baird | → $11 | Initiates Coverage On | → Neutral |
05/24/2022 | 56.39% | Goldman Sachs | $12 → $9 | Maintains | Neutral |
05/05/2022 | 125.89% | Raymond James | $36 → $13 | Maintains | Outperform |
03/07/2022 | 108.51% | Goldman Sachs | $20 → $12 | Maintains | Neutral |
12/14/2021 | 508.17% | RBC Capital | $45 → $35 | Maintains | Outperform |
10/12/2021 | 369.16% | JMP Securities | $53 → $27 | Maintains | Market Outperform |
10/08/2021 | — | Stifel | Downgrades | Buy → Hold | |
10/08/2021 | 681.93% | RBC Capital | $55 → $45 | Maintains | Outperform |
10/08/2021 | 247.52% | Goldman Sachs | $71 → $20 | Downgrades | Buy → Neutral |
09/24/2021 | 525.54% | Raymond James | → $36 | Upgrades | Market Perform → Outperform |
09/23/2021 | 525.54% | Raymond James | → $36 | Upgrades | Market Perform → Outperform |
05/20/2021 | 612.42% | Truist Securities | $34 → $41 | Upgrades | Hold → Buy |
05/14/2021 | 803.56% | B. Riley Securities | → $52 | Initiates Coverage On | → Buy |
03/01/2021 | 647.18% | HC Wainwright & Co. | $40 → $43 | Maintains | Buy |
01/26/2021 | 647.18% | Stifel | $33 → $43 | Upgrades | Hold → Buy |
12/10/2020 | 595.05% | HC Wainwright & Co. | → $40 | Assumes | → Buy |
10/23/2020 | 855.69% | RBC Capital | → $55 | Initiates Coverage On | → Outperform |
06/12/2020 | 751.43% | HC Wainwright & Co. | $55 → $49 | Maintains | Buy |
06/01/2020 | 855.69% | Oppenheimer | $50 → $55 | Maintains | Outperform |
06/01/2020 | — | Raymond James | Downgrades | Outperform → Market Perform | |
05/19/2020 | 942.57% | Roth Capital | → $60 | Upgrades | Neutral → Buy |
05/15/2020 | — | Guggenheim | Upgrades | Neutral → Buy | |
05/14/2020 | 664.55% | Canaccord Genuity | $36 → $44 | Maintains | Buy |
05/14/2020 | 768.81% | Oppenheimer | $44 → $50 | Maintains | Outperform |
05/14/2020 | 629.8% | HC Wainwright & Co. | $35 → $42 | Reiterates | → Buy |
05/14/2020 | 456.04% | SunTrust Robinson Humphrey | $29 → $32 | Downgrades | Buy → Hold |
04/13/2020 | 403.91% | SunTrust Robinson Humphrey | → $29 | Initiates Coverage On | → Buy |
02/24/2020 | 369.16% | Berenberg | → $27 | Initiates Coverage On | → Hold |
12/18/2019 | 542.92% | JMP Securities | → $37 | Initiates Coverage On | → Market Outperform |
11/04/2019 | 525.54% | Canaccord Genuity | → $36 | Initiates Coverage On | → Buy |
08/09/2019 | 542.92% | BTIG | → $37 | Initiates Coverage On | → Buy |
06/05/2019 | 351.78% | Roth Capital | → $26 | Initiates Coverage On | → Neutral |
05/31/2019 | — | Guggenheim | Initiates Coverage On | → Neutral | |
05/23/2019 | 369.16% | Stifel | → $27 | Initiates Coverage On | → Hold |
05/03/2019 | 681.93% | Oppenheimer | → $45 | Initiates Coverage On | → Outperform |
03/29/2019 | 768.81% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
03/15/2019 | 595.05% | Raymond James | → $40 | Initiates Coverage On | → Outperform |
03/14/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
11/05/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
11/05/2018 | 403.91% | JP Morgan | → $29 | Initiates Coverage On | → Neutral |
11/05/2018 | 438.66% | Jefferies | → $31 | Initiates Coverage On | → Buy |
11/05/2018 | 612.42% | Goldman Sachs | → $41 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
07/12/2023 | 212.77% | 信托证券 | 20 美元 → 18 美元 | 维护 | 购买 |
06/26/2023 | 386.53% | 奥本海默 | → 28 美元 | 假设 | → 跑赢大盘 |
06/20/2023 | 299.65% | HC Wainwright & Co. | → 23 美元 | 重申 | 购买 → 购买 |
06/16/2023 | 508.17% | Canaccord Genu | → 35 美元 | 重申 | 购买 → 购买 |
06/05/2023 | 160.64% | JMP 证券 | → 15 美元 | 重申 | → 市场跑赢大盘 |
06/05/2023 | 160.64% | EF Hutton | → 15 美元 | 重申 | 购买 → 购买 |
05/26/2023 | 160.64% | EF Hutton | → 15 美元 | 重申 | 购买 → 购买 |
05/05/2023 | 160.64% | JMP 证券 | 19 美元 → 15 美元 | 维护 | 跑赢大盘 |
05/05/2023 | 299.65% | HC Wainwright & Co. | → 23 美元 | 重申 | → 购买 |
05/04/2023 | 30.32% | Stifel | 8 美元 → 7.5 美元 | 维护 | 保持 |
05/04/2023 | 160.64% | 加拿大皇家银行资本 | → 15 美元 | 重申 | → 跑赢大盘 |
04/20/2023 | 299.65% | HC Wainwright & Co. | → 23 美元 | 重申 | → 购买 |
04/18/2023 | 230.15% | JMP 证券 | → 19 美元 | 重申 | → 市场跑赢大盘 |
04/17/2023 | 160.64% | EF Hutton | → 15 美元 | 维护 | 购买 |
04/04/2023 | 299.65% | HC Wainwright & Co. | 29 美元 → 23 美元 | 维护 | 购买 |
03/21/2023 | 4.26% | 伯恩斯坦 | → 6 美元 | 启动覆盖开启 | → 市场表现 |
03/02/2023 | 438.66% | 高盛 | 35 美元 → 31 美元 | 维护 | 购买 |
03/02/2023 | 230.15% | JMP 证券 | 23 美元 → 19 美元 | 维护 | 市场表现 |
03/01/2023 | 282.28% | 加拿大皇家银行资本 | 32 美元 → 22 美元 | 维护 | 跑赢大盘 |
03/01/2023 | 386.53% | 奥本海默 | 32 美元 → 28 美元 | 维护 | 跑赢大盘 |
03/01/2023 | 438.66% | 高盛 | 35 美元 → 31 美元 | 维护 | 购买 |
03/01/2023 | 160.64% | EF Hutton | → 15 美元 | 重申 | → 购买 |
01/24/2023 | 91.14% | 摩根大通 | 20 美元 → 11 美元 | 升级 | 中性 → 超重 |
01/06/2023 | 108.51% | 贝尔德 | → 12 美元 | 升级 | 中性 → 跑赢大盘 |
01/05/2023 | 160.64% | EF Hutton | → 15 美元 | 启动覆盖开启 | → 购买 |
2022 年 12 月 12 日 | 56.39% | B of A 证券 | → 9 美元 | 降级 | 买入 → 表现不佳 |
11/21/2022 | 403.91% | HC Wainwright & Co. | 43 美元 → 29 美元 | 维护 | 购买 |
2022 年 9 月 22 日 | 212.77% | B. 莱利证券 | 21 美元 → 18 美元 | 维护 | 购买 |
08/10/2022 | 508.17% | 奥本海默 | 40 美元 → 35 美元 | 维护 | 跑赢大盘 |
08/10/2022 | 456.04% | 加拿大皇家银行资本 | 35 美元 → 32 美元 | 维护 | 跑赢大盘 |
08/10/2022 | — | 雷蒙德·詹姆 | 降级 | 跑赢大盘 → 市场表现 | |
07/15/2022 | 456.04% | 高盛 | 9 美元 → 32 美元 | 升级 | 中性 → 买入 |
06/03/2022 | 91.14% | 贝尔德 | → 11 美元 | 启动覆盖开启 | → 中立 |
2022 年 5 月 24 日 | 56.39% | 高盛 | 12 美元 → 9 美元 | 维护 | 中立 |
05/05/2022 | 125.89% | 雷蒙德·詹姆 | 36 美元 → 13 美元 | 维护 | 跑赢大盘 |
03/07/2022 | 108.51% | 高盛 | 20 美元 → 12 美元 | 维护 | 中立 |
12/14/2021 | 508.17% | 加拿大皇家银行资本 | 45 美元 → 35 美元 | 维护 | 跑赢大盘 |
2021 年 12 月 10 日 | 369.16% | JMP 证券 | 53 美元 → 27 美元 | 维护 | 市场跑赢大盘 |
2021 年 8 月 10 日 | — | Stifel | 降级 | 买入 → 持有 | |
2021 年 8 月 10 日 | 681.93% | 加拿大皇家银行资本 | 55 美元 → 45 美元 | 维护 | 跑赢大盘 |
2021 年 8 月 10 日 | 247.52% | 高盛 | 71 美元 → 20 美元 | 降级 | 买入 → 中性 |
2021 年 9 月 24 日 | 525.54% | 雷蒙德·詹姆 | → 36 美元 | 升级 | 市场表现 → 跑赢大盘 |
2021 年 9 月 23 日 | 525.54% | 雷蒙德·詹姆 | → 36 美元 | 升级 | 市场表现 → 跑赢大盘 |
2021 年 5 月 20 日 | 612.42% | 信托证券 | 34 美元 → 41 美元 | 升级 | 持有 → 买入 |
05/14/2021 | 803.56% | B. 莱利证券 | → 52 美元 | 启动覆盖开启 | → 购买 |
2021 年 1 月 3 日 | 647.18% | HC Wainwright & Co. | 40 美元 → 43 美元 | 维护 | 购买 |
2021 年 1 月 26 日 | 647.18% | Stifel | 33 美元 → 43 美元 | 升级 | 持有 → 买入 |
2020 年 10 月 12 日 | 595.05% | HC Wainwright & Co. | → 40 美元 | 假设 | → 购买 |
2020 年 10 月 23 日 | 855.69% | 加拿大皇家银行资本 | → 55 美元 | 启动覆盖开启 | → 跑赢大盘 |
2020 年 12 月 6 日 | 751.43% | HC Wainwright & Co. | 55 美元 → 49 美元 | 维护 | 购买 |
2020 年 1 月 6 日 | 855.69% | 奥本海默 | 50 美元 → 55 美元 | 维护 | 跑赢大盘 |
2020 年 1 月 6 日 | — | 雷蒙德·詹姆 | 降级 | 跑赢大盘 → 市场表现 | |
2020 年 5 月 19 日 | 942.57% | 罗斯资本 | → 60 美元 | 升级 | 中性 → 买入 |
05/15/2020 | — | 古根海姆 | 升级 | 中性 → 买入 | |
05/14/2020 | 664.55% | Canaccord Genu | 36 美元 → 44 美元 | 维护 | 购买 |
05/14/2020 | 768.81% | 奥本海默 | 44 美元 → 50 美元 | 维护 | 跑赢大盘 |
05/14/2020 | 629.8% | HC Wainwright & Co. | 35 美元 → 42 美元 | 重申 | → 购买 |
05/14/2020 | 456.04% | SunTrust 罗宾逊汉弗莱 | 29 美元 → 32 美元 | 降级 | 买入 → 持有 |
2020 年 4 月 13 日 | 403.91% | SunTrust 罗宾逊汉弗莱 | → 29 美元 | 启动覆盖开启 | → 购买 |
2020 年 2 月 24 日 | 369.16% | 贝伦贝格 | → 27 美元 | 启动覆盖开启 | → 按住 |
2019 年 12 月 18 日 | 542.92% | JMP 证券 | → 37 美元 | 启动覆盖开启 | → 市场跑赢大盘 |
11/04/2019 | 525.54% | Canaccord Genu | → 36 美元 | 启动覆盖开启 | → 购买 |
08/09/2019 | 542.92% | BTIG | → 37 美元 | 启动覆盖开启 | → 购买 |
06/05/2019 | 351.78% | 罗斯资本 | → 26 美元 | 启动覆盖开启 | → 中立 |
05/31/2019 | — | 古根海姆 | 启动覆盖开启 | → 中立 | |
05/23/2019 | 369.16% | Stifel | → 27 美元 | 启动覆盖开启 | → 按住 |
05/03/2019 | 681.93% | 奥本海默 | → 45 美元 | 启动覆盖开启 | → 跑赢大盘 |
03/29/2019 | 768.81% | 派珀·桑德勒 | → 50 美元 | 启动覆盖开启 | → 超重 |
03/15/2019 | 595.05% | 雷蒙德·詹姆 | → 40 美元 | 启动覆盖开启 | → 跑赢大盘 |
2019 年 3 月 14 日 | — | 威廉布莱尔 | 启动覆盖开启 | → 跑赢大盘 | |
11/05/2018 | — | Cowen & Co. | 启动覆盖开启 | → 跑赢大盘 | |
11/05/2018 | 403.91% | 摩根大通 | → 29 美元 | 启动覆盖开启 | → 中立 |
11/05/2018 | 438.66% | 杰富瑞 | → 31 美元 | 启动覆盖开启 | → 购买 |
11/05/2018 | 612.42% | 高盛 | → 41 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Allogene Therapeutics (ALLO)?
Allogene Therapeutics(ALLO)的目标价格是多少?
The latest price target for Allogene Therapeutics (NASDAQ: ALLO) was reported by Truist Securities on July 12, 2023. The analyst firm set a price target for $18.00 expecting ALLO to rise to within 12 months (a possible 212.77% upside). 32 analyst firms have reported ratings in the last year.
Truist Securities于2023年7月12日公布了Allogene Therapeutics(纳斯达克股票代码:ALLO)的最新目标股价。这家分析公司将目标股价定为18.00美元,预计ALLO将在12个月内升至12.77%(可能上涨212.77%)。去年有32家分析公司公布了评级。
What is the most recent analyst rating for Allogene Therapeutics (ALLO)?
分析师对Allogene Therapeutics(ALLO)的最新评级是多少?
The latest analyst rating for Allogene Therapeutics (NASDAQ: ALLO) was provided by Truist Securities, and Allogene Therapeutics maintained their buy rating.
Allogene Therapeutics(纳斯达克股票代码:ALLO)的最新分析师评级由Truist Securities提供,Allogene Therapeutics维持买入评级
When is the next analyst rating going to be posted or updated for Allogene Therapeutics (ALLO)?
Allogene Therapeutics(ALLO)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allogene Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allogene Therapeutics was filed on July 12, 2023 so you should expect the next rating to be made available sometime around July 12, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Allogene Therapeutics的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月进行一次评级,因此每家公司每年应该获得4个评级。Allogene Therapeutics的最后一次评级是在2023年7月12日提交的,因此你应该预计下一个评级将在2024年7月12日左右公布。
Is the Analyst Rating Allogene Therapeutics (ALLO) correct?
分析师对Allogene Therapeutics (ALLO) 的评级正确吗
While ratings are subjective and will change, the latest Allogene Therapeutics (ALLO) rating was a maintained with a price target of $20.00 to $18.00. The current price Allogene Therapeutics (ALLO) is trading at is $5.76, which is out of the analyst's predicted range.
尽管评级是主观的,将会发生变化,但最新的Allogene Therapeutics(ALLO)评级维持不变,目标股价为20.00美元至18.00美元。Allogene Therapeutics(ALLO)目前的交易价格为5.76美元,超出了分析师的预测区间。